The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials

BACKGROUND: Migraine is a common neurovascular disorder that has a severe impact on the individual daily life. Atogepant (AGN-241689) is an orally ingested, small-molecule drugs belonging to calcitonin gene-related peptide receptor antagonist, which has been initiated for the prophylactic treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Xinyu, Yan, Zeya, Meng, Jiahao, Wang, Wei, Dai, Qiling, Zhou, Qiufeng, Wang, Zhifeng, Wang, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903713/
https://www.ncbi.nlm.nih.gov/pubmed/35093013
http://dx.doi.org/10.1186/s10194-022-01391-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903713/
https://www.ncbi.nlm.nih.gov/pubmed/35093013
http://dx.doi.org/10.1186/s10194-022-01391-2

Ejemplares similares